Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer

Andreas Schröck; Friederike Göke; Patrick Wagner; Maike Bode; Alina Franzen; Sebastian Huss; Abbas Agaimy; Stephan Ihrler; Robert Kirsten; Glen Kristiansen; Friedrich Bootz; Claudia Lengerke; Sven Perner

doi:10.1002/hed.23443

Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer

Andreas Schröck, Friederike Göke, Patrick Wagner, Maike Bode, Alina Franzen, Sebastian Huss, Abbas Agaimy, Stephan Ihrler, Robert Kirsten, Glen Kristiansen, Friedrich Bootz, Claudia Lengerke, Sven Perner^*

^*Corresponding author for this work

Institute of Pathology

31 Citations (Scopus)

Abstract

Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer. Methods. One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker. Results. FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16. Conclusion. FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer.

Original language	English
Journal	Head and Neck
Volume	36
Issue number	9
Pages (from-to)	1253-1257
Number of pages	5
ISSN	1043-3074
DOIs	https://doi.org/10.1002/hed.23443
Publication status	Published - 09.2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.23443

Cite this

@article{741773de30084ca1a25f20e8b49c1f0b,

title = "Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer",

abstract = "Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer. Methods. One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker. Results. FGFR1 amplification was found in subsets of sinonasal SCCs (20\%), carcinomas associated with an inverted papilloma (33\%), and SNUCs (5\%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16. Conclusion. FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer.",

author = "Andreas Schr{\"o}ck and Friederike G{\"o}ke and Patrick Wagner and Maike Bode and Alina Franzen and Sebastian Huss and Abbas Agaimy and Stephan Ihrler and Robert Kirsten and Glen Kristiansen and Friedrich Bootz and Claudia Lengerke and Sven Perner",

year = "2014",

month = sep,

doi = "10.1002/hed.23443",

language = "English",

volume = "36",

pages = "1253--1257",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley \& Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer

AU - Schröck, Andreas

AU - Göke, Friederike

AU - Wagner, Patrick

AU - Bode, Maike

AU - Franzen, Alina

AU - Huss, Sebastian

AU - Agaimy, Abbas

AU - Ihrler, Stephan

AU - Kirsten, Robert

AU - Kristiansen, Glen

AU - Bootz, Friedrich

AU - Lengerke, Claudia

AU - Perner, Sven

PY - 2014/9

Y1 - 2014/9

N2 - Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer. Methods. One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker. Results. FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16. Conclusion. FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer.

AB - Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer. Methods. One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker. Results. FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16. Conclusion. FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer.

UR - https://www.scopus.com/pages/publications/84906077609

U2 - 10.1002/hed.23443

DO - 10.1002/hed.23443

M3 - Journal articles

C2 - 23913758

AN - SCOPUS:84906077609

SN - 1043-3074

VL - 36

SP - 1253

EP - 1257

JO - Head and Neck

JF - Head and Neck

IS - 9

ER -

Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this